Transcatheter aortic valve replacement before to breast cancer management: case report and literature review.
Heberto Aquino-BrunoRoberto Muratalla-GonzálezJuan F Garcia-GarciaJulieta D Morales-PortanoGabriela Melendez-RamirezYusihey Ahu-ChandomiJose A Merino-RajmeMarco A Alcantara-MeléndezPublished in: European heart journal. Case reports (2024)
Cancer patients may be further disadvantaged by AS if it interferes with their treatment by increasing the risk associated with oncologic surgery and compounding the risks associated with cardiotoxicity and HF. Clinical trials and guidelines on TAVR exclude cohorts with limited life expectancy. Hence, the correct and optimal care for cancer patients with severe AS is complex. The TAVR, for cancer patients with severe AS, can more frequently be the best clinical choice by avoiding cardiopulmonary bypass, minimal invasiveness, and therefore, shorter recovery time.
Keyphrases
- transcatheter aortic valve replacement
- aortic valve
- aortic stenosis
- papillary thyroid
- clinical trial
- squamous cell
- healthcare
- minimally invasive
- early onset
- squamous cell carcinoma
- prostate cancer
- lymph node metastasis
- coronary artery bypass
- ejection fraction
- childhood cancer
- heart failure
- randomized controlled trial
- quality improvement
- clinical practice
- risk assessment
- combination therapy
- study protocol
- acute heart failure
- breast cancer risk